Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2012 | 05:51pm CEST

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; [email protected]

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
04/25 MERCK : MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
04/25 Fresenius picks up M&A pace with Akorn, Merck KGaA deals
04/25DJFRESENIUS : Makes Two Acquisitions to Boost Kabi Clinical Unit
04/24 MERCK : Darmstadt, Germany Divests Biosimilars Business to Fresenius
04/24DJFresenius Kabi To Strengthen And Diversify Product Portfolio By Acquiring Ako..
04/24 AWARE FOR ALL : CISCRP's Clinical Research Education Event Returning to Houston ..
04/20 MERCK : Researchers from Merck KGaA Describe Findings in Granulocytes (Compariso..
04/20 Merck to expand online business 'dramatically'
04/18 MERCK : Darmstadt, Germany Furthers Commitment Towards Elimination of Schistosom..
04/14 Slab Gel Electrophoresis Market 2017 - 3M Purification, Merck KGaA, AB Sciex,..
More news
Sector news : Specialty & Advanced Pharmaceuticals
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/26DJGLAXOSMITHKLINE : Glaxo's New Boss Emma Walmsley Seeks Sharper R&D Edge--Update
04/26DJGLAXOSMITHKLINE : Net Income Boosted by Strong Sales, Weak Pound
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
04/26 Fresenius Shows Biotech How To Get The Deals Done
04/25 FOCUS ON EUROPE : Gearing Up For Q1 Results!
04/15 The Market Is Going To Fall - My Dividend Growth Shopping List
03/31 AMERICAN ASSOCIATION FOR CANCER RESE : Combinations, Oncolytic Viruses, And More
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
Financials (€)
Sales 2017 15 585 M
EBIT 2017 3 307 M
Net income 2017 1 846 M
Debt 2017 9 715 M
Yield 2017 1,18%
P/E ratio 2017 25,01
P/E ratio 2018 21,19
EV / Sales 2017 1,51x
EV / Sales 2018 1,34x
Capitalization 13 835 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA7.97%15 143
ABBVIE INC3.26%103 742
More Results